Rolf Bergman

Title: Rolf Bergman: Innovator in Antibacterial Agents

Introduction

Rolf Bergman, located in Mölndal, Sweden, is a distinguished inventor recognized for his significant contributions to the field of antibacterial agents. He holds a remarkable patent that encapsulates his innovative approach towards new medicinal compounds.

Latest Patents

Bergman’s sole patent, titled "Compounds useful as antibacterial agents," presents novel compounds of Formula I and their pharmaceutically acceptable salts. This invention centers around nitric oxide releasing derivatives of proton pump inhibitors (NO-releasing PPIs). The patent encompasses various aspects, including the preparation processes for these compounds, their pharmaceutical compositions, and their applications in therapies. It also incorporates the co-administration of NO-releasing PPIs alongside other known medicaments, emphasizing the versatility and potential of his inventions.

Career Highlights

Rolf Bergman is currently associated with AstraZeneca AB, a well-respected pharmaceutical company. His role at AstraZeneca allows him to engage in pioneering research and development focused on enhancing healthcare through innovative solutions.

Collaborations

In his innovative journey, Bergman has worked alongside notable coworkers including Arne T. Eek and Lars-Inge Olsson. Their collaboration has contributed to the advancement of compounds that aim to combat bacterial infections, offering new avenues for therapeutic interventions.

Conclusion

Rolf Bergman's contributions as an inventor are marked by his singular patent on antibacterial agents. His work, particularly within AstraZeneca, continues to push the boundaries of what is possible in medicine, promoting better health outcomes through innovative pharmaceutical agents. His dedication to research and development serves as an inspiration for future innovations in the field.